FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:743-744 August 19, 2004 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Until recently, antiviral drugs were both uncommon and not terribly potent. This has changed: during the past decade, more than 30 antiviral drugs have been licensed, and many of them are very effective. Most of the drugs inhibit the activity of viral enzymes, but a new class of agents that block entry of the virus into the cell is being developed. The development of entry inhibitors is driven by the identification of the cell-surface receptors to which viruses bind and by new findings about viral protein structures that bind receptors and mediate viral entry. These advances offer exciting opportunities for . . . [Full Text of this Article]

Source Information

From the Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia.

This article has been cited by other articles:

• Tremblay, C. L., Giguel, F., Guan, Y., Chou, T.-C., Takashima, K., Hirsch, M. S. (2005). TAK-220, a Novel Small-Molecule CCR5 Antagonist, Has Favorable Anti-Human Immunodeficiency Virus Interactions with Other Antiretrovirals In Vitro. Antimicrob. Agents Chemother. 49: 3483-3485 [Abstract] [Full Text]